CJC-1295 without DAC: Dosing Protocols

Research Dosing Disclaimer#

CJC-1295 without DAC (Modified GRF 1-29) is an investigational compound that has not been approved for clinical use by any regulatory agency. No formal clinical dose-finding studies have been published specifically for the non-DAC form. The dosing information below is derived from the broader GHRH analog literature, pharmacological reasoning based on receptor saturation kinetics, and commonly referenced research protocols. This information is for educational purposes only and does not constitute medical advice.

Dosing Rationale#

Receptor Saturation Pharmacology#

The dosing approach for Modified GRF(1-29) is based on the concept of GHRH receptor saturation on pituitary somatotroph cells. The GHRH receptor has a finite number of binding sites, and once these sites are fully occupied, additional peptide does not produce proportionally greater GH release. This creates a saturation dose above which increasing the dose produces diminishing returns.

Based on pharmacological modeling and extrapolation from published GHRH studies, the estimated saturation dose for Modified GRF(1-29) is approximately 1 to 2 micrograms per kilogram of body weight, which corresponds to approximately 100 to 200 micrograms (0.1 to 0.2 mg) for a typical adult. This is the dose range most commonly referenced in research contexts.

Frequency and Timing#

The short half-life of approximately 30 minutes necessitates multiple daily injections to achieve sustained GH axis stimulation. The most commonly discussed protocol involves 2 to 3 injections per day, timed to coincide with natural somatostatin troughs for maximal GH response.

The timing of injections is an important consideration because the GH response to GHRH is modulated by somatostatin tone. Natural somatostatin levels are lowest during sleep (particularly in the first 1 to 2 hours after sleep onset), upon waking in the morning, and approximately 3 hours after meals (when postprandial somatostatin elevation has subsided).

Conversely, the GH response to GHRH is blunted immediately after meals (when somatostatin is elevated), during periods of hyperglycemia, and during early waking hours when cortisol is peaking.

Based on these physiological considerations, the most commonly discussed injection timing is before sleep (to amplify the nocturnal GH surge), upon waking (during the pre-breakfast somatostatin trough), and optionally mid-afternoon (at least 3 hours after the last meal).

Combination Protocols with Ghrelin-Mimetic Peptides#

The most widely discussed use of Modified GRF(1-29) in research settings is in combination with ghrelin-mimetic peptides, particularly ipamorelin. The rationale for this combination is the well-documented synergy between GHRH and ghrelin pathways for GH stimulation.

The standard combination protocol typically involves 100 micrograms of Modified GRF(1-29) combined with 100 to 200 micrograms of ipamorelin, administered subcutaneously 2 to 3 times daily. Both peptides may be drawn into the same syringe and injected simultaneously, as there is no known chemical incompatibility in solution.

The synergistic interaction means that the combined GH response is substantially greater than the sum of the individual responses. Studies with native GHRH combined with ghrelin or GHRP-6 have demonstrated 3- to 5-fold amplification of GH peak levels compared to either agent alone. However, formal dose-optimization studies for the Modified GRF(1-29) plus ipamorelin combination have not been published.

Administration Technique#

Modified GRF(1-29) is administered via subcutaneous injection. The injection technique follows standard subcutaneous administration practices: a 27- to 31-gauge, 0.5-inch insulin syringe is used to inject the reconstituted peptide solution into a pinched fold of skin at a 45-degree angle.

Recommended injection sites include the lower abdominal area (at least 2 inches from the navel), the anterior thigh, and the upper arm. Rotation of injection sites between injections is recommended to minimize the risk of lipodystrophy or injection site reactions.

The injection should ideally be performed on an empty stomach (at least 2 to 3 hours after the last meal) to avoid the blunting effect of postprandial somatostatin elevation on GH release. Avoiding food for approximately 30 minutes after injection is also commonly recommended, as the glucose and insulin elevations from eating can attenuate the GH response.

Reconstitution Instructions#

Modified GRF(1-29) is typically supplied as a lyophilized powder in sealed glass vials (commonly 2 mg or 5 mg). Reconstitution should be performed using bacteriostatic water for injection (containing 0.9% benzyl alcohol as a preservative), which allows the reconstituted solution to be stored for multiple doses.

To reconstitute, clean the vial stopper with an alcohol swab, draw the desired volume of bacteriostatic water into a syringe, and slowly inject it into the vial, directing the stream against the glass wall. Allow the peptide to dissolve by gentle swirling; do not shake. The reconstituted solution should be clear and colorless.

For a 2 mg vial reconstituted with 1 mL of bacteriostatic water, the concentration is 2 mg/mL (2000 mcg/mL). A 100 mcg dose would require drawing 0.05 mL (5 units on a 100-unit insulin syringe).

Storage and Stability#

Lyophilized Modified GRF(1-29) should be stored at -20 degrees Celsius or colder. At this temperature, the peptide is stable for extended periods. The reconstituted solution should be stored refrigerated at 2 to 8 degrees Celsius and used within 14 to 21 days. The solution should not be frozen after reconstitution, and should be protected from light.

The four amino acid modifications substantially improve the stability of Modified GRF(1-29) compared to native GRF(1-29) (sermorelin), both in the lyophilized state and in reconstituted solution. However, as with all peptides, exposure to heat, repeated freeze-thaw cycles, or prolonged storage in solution will gradually reduce potency.

Related Reading#

• CJC-1295 without DAC overview and research guide
• CJC-1295 without DAC side effects profile
• CJC-1295 without DAC research evidence